{"gene":"AGT","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":1992,"finding":"Molecular variants of angiotensinogen (AGT), particularly M235T, are genetically linked to essential hypertension in two independent human cohorts, and plasma angiotensinogen concentrations differ significantly among hypertensive subjects with different AGT genotypes, establishing AGT as a genetic determinant of angiotensinogen levels and blood pressure.","method":"Genetic linkage analysis of hypertensive sibships + plasma angiotensinogen quantification stratified by genotype","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — replicated in two geographically separate cohorts with functional plasma level data","pmids":["1394429"],"is_preprint":false},{"year":1993,"finding":"The T235 molecular variant of angiotensinogen is significantly associated with preeclampsia in Caucasian and Japanese women, corroborating and extending the link between AGT variants and hypertensive disorders of pregnancy.","method":"Genetic association study in two independent ethnically distinct cohorts (Caucasian and Japanese)","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — replicated across two independent populations with consistent direction of effect","pmids":["8513325"],"is_preprint":false},{"year":1997,"finding":"A common nucleotide substitution in the proximal AGT promoter (G-to-A at position −6 upstream of transcription initiation) is associated with essential hypertension and directly reduces basal transcription rate of the AGT gene, as demonstrated by promoter-reporter assays and electrophoretic mobility shift assays showing altered nuclear protein binding at this element.","method":"Promoter-reporter (luciferase/CAT) assays + EMSA with nuclear proteins; genetic association in hypertensive subjects","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1-2 — direct functional assay (reporter + EMSA) combined with human genetic association, replicated finding","pmids":["9120024"],"is_preprint":false},{"year":1998,"finding":"Human adipose tissue expresses angiotensinogen mRNA and protein, as well as renin, angiotensin-converting enzyme, cathepsin D, and cathepsin G, establishing that angiotensinogen can be processed locally within adipose tissue to produce angiotensin II independently of the circulating renin-angiotensin system.","method":"Northern blot (angiotensinogen mRNA), Western blot (angiotensinogen protein in isolated adipocytes), RT-PCR + Southern blot (renin, ACE, cathepsin D, cathepsin G mRNAs) with restriction enzyme verification","journal":"The Journal of clinical endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (Northern, Western, RT-PCR) in same study confirming local RAS components","pmids":["9814470"],"is_preprint":false},{"year":2000,"finding":"The T235 allele of the AGT gene is associated with greater stimulation of plasma AGT secretion after ethinylestradiol administration in normotensive men, resulting in higher peak plasma AGT concentrations in TT versus MM homozygotes; the renin-angiotensin system readjusts through decreased renin release, blunting the physiological impact of elevated AGT.","method":"Controlled pharmacological challenge (ethinylestradiol ± furosemide/captopril) with plasma AGT, renin activity, and active renin measurements in TT vs MM homozygous men","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — controlled in vivo challenge in human subjects with direct hormone measurements, single lab","pmids":["11095476"],"is_preprint":false},{"year":2002,"finding":"The renin receptor binds renin and prorenin at the cell surface and, upon renin binding, increases the catalytic efficiency of angiotensinogen conversion to angiotensin I by fourfold, while also activating intracellular MAP kinase signaling (ERK1/ERK2 phosphorylation); the receptor is localized to mesangial glomerular cells and subendothelium co-localizing with renin.","method":"Expression cloning; radioligand binding assays; angiotensinogen conversion kinetic assays; phosphorylation/MAP kinase activation assays; confocal microscopy for colocalization","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1-2 — reconstituted binding and kinetic assay with multiple orthogonal methods in a single rigorous study","pmids":["12045255"],"is_preprint":false},{"year":2006,"finding":"IFN-γ upregulates AGT mRNA and promoter activity in hepatocytes through a STAT1-binding element located between −271 and −279 bp in the AGT promoter; EMSA and ChIP assays confirm IFN-γ–induced STAT1 binding to this element, and mutation of the STAT1 site in the full-length promoter reduces IFN-γ responsiveness, defining a pathway distinct from the IL-6/STAT3 or dexamethasone/GR mechanisms.","method":"Promoter deletion reporter assays, EMSA, chromatin immunoprecipitation (ChIP), site-directed mutagenesis of STAT1 element in hepatocytes (Hep3B)","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (reporter, EMSA, ChIP, mutagenesis) in single study","pmids":["16949687"],"is_preprint":false},{"year":2017,"finding":"AGT knockdown in IL-6-stimulated chondrocytes inhibits increases in IL-1β, MMP-13, and nitrite through blocking the renin-angiotensin system; miR-149-5p directly targets the AGT 3′UTR (validated by luciferase reporter and mutant constructs), suppressing AGT expression and thereby attenuating JAK2/STAT3 pathway activation and inflammatory responses in osteoarthritis chondrocytes.","method":"Loss-of-function siRNA knockdown; luciferase reporter assay with wild-type and mutant AGT 3′UTR; JAK2/STAT3 pathway inhibitor treatment; RT-qPCR and Western blot in IL-6-stimulated HC-a cells and OA patient cartilage","journal":"Clinical and experimental rheumatology","confidence":"Medium","confidence_rationale":"Tier 2-3 — validated miRNA-target interaction with luciferase reporter + functional KD with pathway readout, single lab","pmids":["32141427"],"is_preprint":false},{"year":2017,"finding":"miR-29a directly targets the AGT 3′UTR and negatively regulates AGT mRNA and protein expression in a rat diabetic retinopathy model; overexpression of miR-29a reduces AGT expression, vascular density, and retinal neovascularization, while knockdown of miR-29a has the opposite effect, establishing an miR-29a→AGT regulatory axis controlling retinal angiogenesis.","method":"qRT-PCR, Western blot, ADPase histochemical staining of retinal neovascularization, H&E staining; miR-29a overexpression and knockdown in DR rat model and AR42J cells","journal":"Experimental and molecular pathology","confidence":"Medium","confidence_rationale":"Tier 2-3 — in vivo functional data with multiple readouts, single lab, no direct luciferase validation of AGT 3′UTR in this paper","pmids":["28189547"],"is_preprint":false},{"year":2017,"finding":"miR-29a suppresses AGT mRNA and protein expression in oxygen-induced retinopathy mouse models; AGT knockdown via si-AGT phenocopies miR-29a overexpression, reducing VEGF, HGF, angiotensin, and angiotensin II protein levels and decreasing retinal neovascularization, placing AGT upstream of angiogenic factor production in ROP pathology.","method":"qRT-PCR, Western blot (AGT, VEGF, HGF, ANG, AngII), ADPase histochemical staining, H&E staining; miR-29a mimics/inhibitors and si-AGT in OIR mouse model","journal":"American journal of translational research","confidence":"Medium","confidence_rationale":"Tier 2-3 — functional in vivo with multiple downstream protein readouts; independent confirmation of miR-29a/AGT axis","pmids":["28337307"],"is_preprint":false},{"year":2017,"finding":"In AGT-REN double transgenic hypertensive mice, elevated angiotensin II increases myocardial oxidative stress (elevated MDA, reduced SOD activity), which upregulates KCa3.1 channel protein expression via the ERK1/2 pathway, promoting cardiac fibroblast proliferation and myocardial fibrosis; blockade of ROS (NAC, apocynin) or ERK1/2 (PD98059) reduces KCa3.1 expression and fibrosis.","method":"AGT-REN double transgenic mouse model; TRAM-34/losartan/NAC/apocynin/PD98059 pharmacological interventions; Western blot (KCa3.1, p-ERK1/2, β-MHC); biochemical assays (MDA, SOD); histological collagen staining","journal":"Pflugers Archiv : European journal of physiology","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo transgenic model with multiple pharmacological interventions and defined pathway readouts, single lab","pmids":["28455747"],"is_preprint":false},{"year":2021,"finding":"EPI (epiberberine) reduces AGT expression in glomerular mesangial cells and db/db diabetic mice, and AGT siRNA knockdown attenuates proliferation, G2/M arrest, and TGFβ1/Smad2 expression, establishing AGT as an upstream activator of the TGFβ/Smad2 fibrotic pathway in diabetic nephropathy; molecular docking and RNA-seq identified AGT as the key therapeutic target of EPI.","method":"RNA-seq of kidney tissue; molecular docking; siRNA knockdown in HG-stimulated glomerular mesangial cells; Western blot (AGT, TGFβ1, Smad2); in vivo db/db mouse treatment with histopathology and renal function assays","journal":"Phytomedicine","confidence":"Medium","confidence_rationale":"Tier 2 — siRNA epistasis + in vivo validation with multiple readouts; AGT→TGFβ/Smad2 pathway placement by two orthogonal approaches","pmids":["33571918"],"is_preprint":false},{"year":2021,"finding":"DNA methylation at CCAAT-enhancer-binding-protein (CEBP) sites in the AGT promoter negatively regulates AGT expression; high salt intake and excess aldosterone cause DNA demethylation at these sites in visceral adipose tissue and heart, converting AGT expression from inactive to active state; low DNA methylation at CEBP-binding sites is associated with increased cardiac AGT expression in salt-sensitive hypertension.","method":"Bisulfite sequencing/methylation analysis of AGT promoter; ChIP for CEBP binding; comparison of salt-sensitive hypertensive rats vs controls; human cardiac tissue analysis","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2-3 — epigenomic mechanistic data with in vivo correlation, multiple tissues examined","pmids":["33925539"],"is_preprint":false},{"year":2021,"finding":"AGT promotes colorectal carcinoma cell proliferation, migration, invasion, and HUVEC angiogenesis (induced by CRC-conditioned medium); AGT expression correlates with isoliquiritigenin drug sensitivity, and ISL suppresses CRC progression in vitro.","method":"In vitro functional assays (proliferation, migration, invasion, angiogenesis) in CRC cell lines; conditional medium HUVEC angiogenesis assay; drug response analysis (CCLE, CTRP)","journal":"International immunopharmacology","confidence":"Low","confidence_rationale":"Tier 3 — functional cell assays without defined molecular mechanism or pathway placement for AGT","pmids":["34655849"],"is_preprint":false},{"year":2021,"finding":"Antisense oligonucleotide IONIS-AGT-LRx, administered subcutaneously, significantly reduces plasma angiotensinogen (AGT) protein levels in hypertensive humans in three separate controlled clinical trials, with a favorable safety profile and trends toward blood pressure reduction.","method":"Double-blind placebo-controlled Phase 1 and Phase 2 clinical trials; plasma AGT levels measured as pharmacodynamic endpoint","journal":"JACC. Basic to translational science","confidence":"High","confidence_rationale":"Tier 2 — three independent clinical trials demonstrating on-target AGT reduction in humans with antisense inhibition","pmids":["34222719"],"is_preprint":false},{"year":2023,"finding":"AGT knockdown in gastric cancer cells reduces proliferation and migration, and impairs TGFβ/PI3K/AKT-mediated epithelial-mesenchymal transition (EMT); PI3K/AKT agonist 740Y-P rescues EMT impaired by AGT knockdown and 5-fluorouracil treatment, placing AGT upstream of PI3K/AKT→EMT signaling in gastric cancer and establishing that AGT loss enhances chemotherapy sensitivity in vitro and in vivo.","method":"siRNA knockdown of AGT in GC cell lines; Western blot (EMT markers, PI3K/AKT); PI3K/AKT agonist rescue experiment; in vivo xenograft tumor growth assay; bioinformatics risk signature from TCGA/GEO","journal":"Pharmaceutics","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis (rescue experiment) placing AGT in PI3K/AKT/EMT pathway with in vivo validation","pmids":["36986671"],"is_preprint":false}],"current_model":"Angiotensinogen (AGT) is a hepatocyte-secreted α2-globulin and the obligate precursor of angiotensin peptides whose expression is transcriptionally upregulated by IFN-γ via a STAT1-binding promoter element and by cytokine/steroid signaling, and is epigenetically regulated by DNA methylation at CEBP sites; AGT is also expressed locally in adipose tissue where the full enzymatic machinery for angiotensin II production is present; the M235T and G-6A promoter variants directly alter plasma AGT levels and basal transcription rate, respectively, predisposing to hypertension and preeclampsia; beyond the classical renin-angiotensin axis, AGT activates downstream JAK2/STAT3 and TGFβ/Smad2 and PI3K/AKT/EMT signaling pathways in inflammatory and oncogenic contexts, and is negatively regulated post-transcriptionally by miR-29a and miR-149-5p."},"narrative":{"teleology":[{"year":1992,"claim":"Establishing AGT as a genetic determinant of blood pressure answered whether angiotensinogen itself—not just downstream RAS components—could be rate-limiting for hypertension risk.","evidence":"Genetic linkage analysis of hypertensive sibships in two independent cohorts with plasma AGT quantification stratified by M235T genotype","pmids":["1394429"],"confidence":"High","gaps":["Whether M235T is causal or in linkage disequilibrium with the true functional variant","Mechanism by which M235T alters AGT secretion or stability unresolved"]},{"year":1993,"claim":"Extension of the AGT T235 association to preeclampsia demonstrated that this variant predisposes to hypertensive disorders beyond essential hypertension, broadening the clinical significance of AGT variation.","evidence":"Genetic association study in independent Caucasian and Japanese cohorts of preeclamptic women","pmids":["8513325"],"confidence":"High","gaps":["Molecular mechanism linking elevated AGT to placental pathology not defined","Whether preeclampsia risk is mediated by maternal or fetal AGT genotype unclear"]},{"year":1997,"claim":"Identification of the G-6A promoter variant as a functional cis-regulatory element resolved how a non-coding AGT variant directly alters transcription rate and nuclear protein binding, mechanistically linking promoter variation to plasma AGT levels.","evidence":"Promoter-reporter assays (luciferase/CAT) and EMSA with nuclear extracts in human cells, plus genetic association","pmids":["9120024"],"confidence":"High","gaps":["Identity of the nuclear factor whose binding is altered at −6 not determined","Contribution of G-6A versus M235T in cis not fully disentangled"]},{"year":1998,"claim":"Demonstrating local AGT expression together with renin, ACE, and cathepsins in adipose tissue established that angiotensin II can be generated in a tissue-autonomous manner, independent of hepatic secretion.","evidence":"Northern blot, Western blot, RT-PCR with restriction verification in human adipocytes","pmids":["9814470"],"confidence":"High","gaps":["Quantitative contribution of adipose-derived versus hepatic AGT to circulating angiotensin peptides unknown","Regulatory signals controlling adipose AGT expression not characterized"]},{"year":2002,"claim":"Discovery that the renin receptor enhances AGT-to-angiotensin I conversion fourfold upon renin binding provided a cell-surface mechanism amplifying local RAS activity and added a non-proteolytic signaling dimension (ERK1/2) to renin–AGT interaction.","evidence":"Expression cloning, radioligand binding, kinetic conversion assays, and ERK phosphorylation assays with confocal colocalization in mesangial cells","pmids":["12045255"],"confidence":"High","gaps":["Whether the renin receptor alters AGT conformation or merely concentrates renin at the surface not resolved","In vivo contribution of receptor-bound versus soluble renin to AGT cleavage not quantified"]},{"year":2006,"claim":"Mapping a STAT1-binding element in the AGT promoter responsive to IFN-γ defined a cytokine-driven transcriptional pathway for AGT distinct from the known IL-6/STAT3 and glucocorticoid mechanisms, linking innate immune activation to RAS induction.","evidence":"Promoter deletion reporters, EMSA, ChIP, and site-directed mutagenesis in Hep3B hepatocytes","pmids":["16949687"],"confidence":"High","gaps":["Whether STAT1-driven AGT induction occurs in non-hepatic tissues not tested","Physiological contexts in which IFN-γ-mediated AGT upregulation is rate-limiting for angiotensin II generation unknown"]},{"year":2017,"claim":"Identification of miR-29a and miR-149-5p as direct post-transcriptional repressors of AGT via its 3′UTR established a new regulatory layer, with functional consequences for retinal neovascularization (miR-29a) and chondrocyte inflammation through JAK2/STAT3 (miR-149-5p).","evidence":"Luciferase 3′UTR reporter with wild-type and mutant constructs (miR-149-5p); miR-29a overexpression/knockdown in diabetic retinopathy and OIR rodent models with AGT protein and angiogenic readouts; siRNA epistasis in chondrocytes","pmids":["32141427","28189547","28337307"],"confidence":"Medium","gaps":["miR-29a targeting of AGT 3′UTR lacks direct luciferase validation in the cited study","Whether these miRNAs regulate hepatic AGT output in vivo not examined","Relative contribution of AGT suppression versus other targets of miR-29a to the anti-angiogenic phenotype unresolved"]},{"year":2017,"claim":"AGT-REN double transgenic mice demonstrated that sustained AGT/angiotensin II elevation drives myocardial fibrosis via ROS-mediated ERK1/2 activation of KCa3.1 channels, placing AGT upstream of oxidative-stress-dependent ion channel remodeling in cardiac fibroblasts.","evidence":"Double transgenic mouse model with pharmacological interventions (losartan, NAC, apocynin, PD98059, TRAM-34); Western blot and biochemical assays for pathway components","pmids":["28455747"],"confidence":"Medium","gaps":["Whether KCa3.1 upregulation is a direct consequence of angiotensin II receptor signaling or secondary to ROS accumulation not fully dissected","Single lab; independent replication pending"]},{"year":2021,"claim":"Epigenetic regulation of AGT was defined by showing that DNA methylation at CEBP sites in the AGT promoter acts as an on/off switch: demethylation by high salt and aldosterone activates AGT transcription in adipose and cardiac tissue, linking dietary and hormonal inputs to epigenomic control of local RAS.","evidence":"Bisulfite sequencing and ChIP for CEBP binding in salt-sensitive hypertensive rats and human cardiac tissue","pmids":["33925539"],"confidence":"Medium","gaps":["Causal relationship between demethylation and CEBP binding not established by interventional demethylation","Whether methylation changes are reversible upon salt restriction not tested"]},{"year":2021,"claim":"Placing AGT upstream of TGFβ/Smad2 signaling in diabetic nephropathy and demonstrating that AGT knockdown attenuates fibrotic responses in mesangial cells broadened AGT's effector role beyond hemodynamics to organ fibrosis.","evidence":"siRNA knockdown in high-glucose-stimulated mesangial cells with Western blot for TGFβ1/Smad2; in vivo validation in db/db mice treated with epiberberine","pmids":["33571918"],"confidence":"Medium","gaps":["Whether fibrotic effect is mediated by angiotensin II or by intact AGT protein not distinguished","Specificity of epiberberine for AGT versus off-target effects not fully controlled"]},{"year":2021,"claim":"Antisense oligonucleotide-mediated AGT suppression in hypertensive humans validated AGT as a druggable therapeutic target, providing clinical proof-of-concept that reducing the precursor pool itself can modulate RAS activity.","evidence":"Phase 1 and Phase 2 double-blind placebo-controlled trials of IONIS-AGT-LRx with plasma AGT as pharmacodynamic endpoint","pmids":["34222719"],"confidence":"High","gaps":["Long-term safety and blood-pressure efficacy not yet established in Phase 3 trials","Effect on tissue (non-hepatic) AGT pools not assessed"]},{"year":2023,"claim":"Demonstration that AGT knockdown impairs PI3K/AKT-mediated EMT in gastric cancer—rescued by a PI3K agonist—positioned AGT as an upstream activator of an oncogenic signaling axis and suggested AGT loss sensitizes tumors to 5-fluorouracil.","evidence":"siRNA knockdown with PI3K/AKT agonist rescue in GC cell lines; Western blot for EMT markers; xenograft tumor growth assay","pmids":["36986671"],"confidence":"Medium","gaps":["Whether the oncogenic effect requires angiotensin II generation or is a direct property of AGT protein not resolved","Relevance to human gastric cancer in vivo beyond xenograft models not established"]},{"year":null,"claim":"It remains unresolved whether AGT exerts signaling functions independent of its cleavage to angiotensin peptides, and structural determinants of variant-specific differences in renin cleavage efficiency or secretion rate have not been defined.","evidence":"","pmids":[],"confidence":"High","gaps":["No crystal structure of full-length human AGT in complex with renin to explain M235T kinetic differences","Angiotensin-independent functions of intact AGT protein not tested by cleavage-resistant mutants","Relative contribution of hepatic versus tissue-specific AGT to local and systemic angiotensin generation in humans not quantified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[5,10,11,15]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,3,4,14]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,7,10,11,15]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[0,2,14]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,13,15]}],"complexes":[],"partners":["REN","ATP6AP2","ACE","TGFB1","SMAD2"],"other_free_text":[]},"mechanistic_narrative":"Angiotensinogen (AGT) is the obligate secreted precursor of the angiotensin peptide family and a central determinant of renin–angiotensin system (RAS) activity, blood pressure homeostasis, and tissue-level angiotensin II signaling. The M235T coding variant and G-6A promoter variant directly modulate plasma AGT levels and basal transcription rate, respectively, conferring genetic susceptibility to essential hypertension and preeclampsia [PMID:1394429, PMID:8513325, PMID:9120024]. AGT transcription in hepatocytes is upregulated by IFN-γ through a STAT1-binding promoter element and is epigenetically tuned by DNA methylation at CEBP sites, while post-transcriptionally miR-29a and miR-149-5p target the AGT 3′UTR to suppress expression [PMID:16949687, PMID:33925539, PMID:32141427, PMID:28189547]. Beyond classical renin-mediated cleavage—enhanced by the renin receptor at cell surfaces [PMID:12045255]—AGT is expressed in adipose tissue with a complete local RAS machinery and signals through downstream TGFβ/Smad2, PI3K/AKT/EMT, and JAK2/STAT3 pathways in inflammatory, fibrotic, and oncogenic contexts [PMID:9814470, PMID:33571918, PMID:36986671, PMID:32141427]."},"prefetch_data":{"uniprot":{"accession":"P01019","full_name":"Angiotensinogen","aliases":["Serpin A8"],"length_aa":476,"mass_kda":52.1,"function":"Essential component of the renin-angiotensin system (RAS), a potent regulator of blood pressure, body fluid and electrolyte homeostasis Acts directly on vascular smooth muscle as a potent vasoconstrictor, affects cardiac contractility and heart rate through its action on the sympathetic nervous system, and alters renal sodium and water absorption through its ability to stimulate the zona glomerulosa cells of the adrenal cortex to synthesize and secrete aldosterone (PubMed:10619573, PubMed:17138938). Acts by binding to angiotensin receptors AGTR1 and AGTR2 (PubMed:1567413). Also binds the DEAR/FBXW7-AS1 receptor (By similarity) Stimulates aldosterone release Is a ligand for the G-protein coupled receptor MAS1 (By similarity). Has vasodilator and antidiuretic effects. Has an antithrombotic effect that involves MAS1-mediated release of nitric oxide from platelets (By similarity)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P01019/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/AGT","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/AGT","total_profiled":1310},"omim":[{"mim_id":"615589","title":"OTOSCLEROSIS 10; OTSC10","url":"https://www.omim.org/entry/615589"},{"mim_id":"615309","title":"tRNA THREONINE (ANTICODON AGT) 2-2; TRT-AGT2-2","url":"https://www.omim.org/entry/615309"},{"mim_id":"613113","title":"NEUROFIBROMIN 1; NF1","url":"https://www.omim.org/entry/613113"},{"mim_id":"612624","title":"MICROVASCULAR COMPLICATIONS OF DIABETES, SUSCEPTIBILITY TO, 3; MVCD3","url":"https://www.omim.org/entry/612624"},{"mim_id":"607306","title":"STEROID 5-ALPHA-REDUCTASE 2; SRD5A2","url":"https://www.omim.org/entry/607306"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"liver","ntpm":1554.9}],"url":"https://www.proteinatlas.org/search/AGT"},"hgnc":{"alias_symbol":[],"prev_symbol":["SERPINA8"]},"alphafold":{"accession":"P01019","domains":[{"cath_id":"3.30.497.10","chopping":"81-283_385-429","consensus_level":"medium","plddt":91.0668,"start":81,"end":429},{"cath_id":"2.30.39.10","chopping":"289-382_439-477","consensus_level":"medium","plddt":88.1668,"start":289,"end":477}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P01019","model_url":"https://alphafold.ebi.ac.uk/files/AF-P01019-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P01019-F1-predicted_aligned_error_v6.png","plddt_mean":86.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=AGT","jax_strain_url":"https://www.jax.org/strain/search?query=AGT"},"sequence":{"accession":"P01019","fasta_url":"https://rest.uniprot.org/uniprotkb/P01019.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P01019/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P01019"}},"corpus_meta":[{"pmid":"15221026","id":"PMC_15221026","title":"DNA binding and nucleotide flipping by the human DNA repair protein AGT.","date":"2004","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15221026","citation_count":258,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10747039","id":"PMC_10747039","title":"Active and alkylated human AGT structures: a novel zinc site, inhibitor and extrahelical base binding.","date":"2000","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10747039","citation_count":175,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15077204","id":"PMC_15077204","title":"Natural selection and population history in the human angiotensinogen gene (AGT): 736 complete AGT sequences in chromosomes from around the world.","date":"2004","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15077204","citation_count":103,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17107992","id":"PMC_17107992","title":"ACE I/D but not AGT (-6)A/G polymorphism is a risk factor for mortality in ARDS.","date":"2006","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/17107992","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17027096","id":"PMC_17027096","title":"Primary hyperoxaluria type 1: AGT mistargeting highlights the fundamental differences between the peroxisomal and mitochondrial protein import pathways.","date":"2006","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/17027096","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15964013","id":"PMC_15964013","title":"The structure of the human AGT protein bound to DNA and its implications for damage detection.","date":"2005","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15964013","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34222719","id":"PMC_34222719","title":"Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx: Results of Phase 1 and Phase 2 Studies.","date":"2021","source":"JACC. Basic to translational science","url":"https://pubmed.ncbi.nlm.nih.gov/34222719","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18353991","id":"PMC_18353991","title":"A two-step nucleotide-flipping mechanism enables kinetic discrimination of DNA lesions by AGT.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18353991","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12404103","id":"PMC_12404103","title":"Detection of putative functional angiotensinogen (AGT) gene variants controlling plasma AGT levels by combined segregation-linkage analysis.","date":"2002","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/12404103","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10899077","id":"PMC_10899077","title":"AGT M235T and ACE ID polymorphisms and exercise blood pressure in the HERITAGE Family Study.","date":"2000","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10899077","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16925018","id":"PMC_16925018","title":"Fluorophores for live cell imaging of AGT fusion proteins across the visible spectrum.","date":"2006","source":"BioTechniques","url":"https://pubmed.ncbi.nlm.nih.gov/16925018","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9461232","id":"PMC_9461232","title":"Diabetic nephropathy is associated with AGT polymorphism T235: results of a family-based study.","date":"1998","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/9461232","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28760411","id":"PMC_28760411","title":"Polymorphisms of MTHFR, eNOS, ACE, AGT, ApoE, PON1, PDE4D, and Ischemic Stroke: Meta-Analysis.","date":"2017","source":"Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association","url":"https://pubmed.ncbi.nlm.nih.gov/28760411","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1531616","id":"PMC_1531616","title":"Neocarzinostatin-mediated DNA damage in a model AGT.ACT site: mechanistic studies of thiol-sensitive partitioning of C4' DNA damage products.","date":"1992","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1531616","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21955333","id":"PMC_21955333","title":"4-nitrobenzyloxycarbonyl derivatives of O(6)-benzylguanine as hypoxia-activated prodrug inhibitors of O(6)-alkylguanine-DNA alkyltransferase (AGT), which produces resistance to agents targeting the O-6 position of DNA guanine.","date":"2011","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21955333","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20029521","id":"PMC_20029521","title":"The C allele of the AGT Met235Thr polymorphism is associated with power sports performance.","date":"2009","source":"Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/20029521","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17138560","id":"PMC_17138560","title":"Interactions of human O6-alkylguanine-DNA alkyltransferase (AGT) with short single-stranded DNAs.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17138560","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15044674","id":"PMC_15044674","title":"Adipose angiotensinogen secretion, blood pressure, and AGT M235T polymorphism in obese patients.","date":"2004","source":"Obesity research","url":"https://pubmed.ncbi.nlm.nih.gov/15044674","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18689375","id":"PMC_18689375","title":"Blood pressure and interactions between the angiotensin polymorphism AGT M235T and sodium intake: a cross-sectional population study.","date":"2008","source":"The American journal of clinical nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/18689375","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34643045","id":"PMC_34643045","title":"Endogenous tRNA-derived small RNA (tRF3-Thr-AGT) inhibits ZBP1/NLRP3 pathway-mediated cell pyroptosis to attenuate acute pancreatitis (AP).","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34643045","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23287839","id":"PMC_23287839","title":"Association of rs699 (M235T) polymorphism in the AGT gene with power but not endurance athlete status.","date":"2013","source":"Journal of strength and conditioning research","url":"https://pubmed.ncbi.nlm.nih.gov/23287839","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14704831","id":"PMC_14704831","title":"1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): I. Direct inhibition of O6-alkylguanine-DNA alkyltransferase (AGT) by electrophilic species generated by decomposition.","date":"2003","source":"Cancer chemotherapy and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/14704831","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12497201","id":"PMC_12497201","title":"Differential responses of EGFR-/AGT-expressing cells to the \"combi-triazene\" SMA41.","date":"2002","source":"Cancer chemotherapy and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12497201","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32141427","id":"PMC_32141427","title":"AGT, targeted by miR-149-5p, promotes IL-6-induced inflammatory responses of chondrocytes in osteoarthritis via activating JAK2/STAT3 pathway.","date":"2020","source":"Clinical and experimental rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/32141427","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11926202","id":"PMC_11926202","title":"Hypertension after renal transplantation and polymorphism of genes involved in essential hypertension: ACE, AGT, AT1 R and ecNOS.","date":"2002","source":"Clinical nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/11926202","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33925539","id":"PMC_33925539","title":"DNA Methylation of the Angiotensinogen Gene, AGT, and the Aldosterone Synthase Gene, CYP11B2 in Cardiovascular Diseases.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33925539","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8895534","id":"PMC_8895534","title":"Allele-specific PCR analysis of p53 codon 249 AGT transversion in liver tissues from patients with viral hepatitis.","date":"1996","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/8895534","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18575631","id":"PMC_18575631","title":"The M235T polymorphism in the AGT gene and CHD risk: evidence of a Hardy-Weinberg equilibrium violation and publication bias in a meta-analysis.","date":"2008","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18575631","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22148914","id":"PMC_22148914","title":"Gender-related association of AGT gene variants (M235T and T174M) with essential hypertension--a case-control study.","date":"2011","source":"Clinical and experimental hypertension (New York, N.Y. : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/22148914","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19061338","id":"PMC_19061338","title":"Interactions of human O(6)-alkylguanine-DNA alkyltransferase (AGT) with short double-stranded DNAs.","date":"2008","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19061338","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11536039","id":"PMC_11536039","title":"Overexpression of human O6-alkylguanine DNA alkyltransferase (AGT) prevents MNU induced lymphomas in heterozygous p53 deficient mice.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11536039","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21636204","id":"PMC_21636204","title":"Haplotype-based association of ACE I/D, AT1R 1166A>C, and AGT M235T polymorphisms in renin-angiotensin-aldosterone system genes in Korean women with idiopathic recurrent spontaneous abortions.","date":"2011","source":"European journal of obstetrics, gynecology, and reproductive biology","url":"https://pubmed.ncbi.nlm.nih.gov/21636204","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26092580","id":"PMC_26092580","title":"Increased urinary Angiotensinogen/Creatinine (AGT/Cr) ratio may be associated with reduced renal function in autosomal dominant polycystic kidney disease patients.","date":"2015","source":"BMC nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/26092580","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16081100","id":"PMC_16081100","title":"Structural evidence of a passive base-flipping mechanism for AGT, an unusual GT-B glycosyltransferase.","date":"2005","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16081100","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27928207","id":"PMC_27928207","title":"The AGT Gene M235T Polymorphism and Response of Power-Related Variables to Aerobic Training.","date":"2016","source":"Journal of sports science & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27928207","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25031294","id":"PMC_25031294","title":"A polymorphism in AGT and AGTR1 gene is associated with lead-related high blood pressure.","date":"2014","source":"Journal of the renin-angiotensin-aldosterone system : JRAAS","url":"https://pubmed.ncbi.nlm.nih.gov/25031294","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33571918","id":"PMC_33571918","title":"Epiberberine ameliorated diabetic nephropathy by inactivating the angiotensinogen (Agt) to repress TGFβ/Smad2 pathway.","date":"2021","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33571918","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20606419","id":"PMC_20606419","title":"Associations between genetic variants in the ACE, AGT, AGTR1 and AGTR2 genes and renal function in the Multi-ethnic Study of Atherosclerosis.","date":"2010","source":"American journal of nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/20606419","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18849600","id":"PMC_18849600","title":"Gender-dependent effect of ACE I/D and AGT M235T polymorphisms on the progression of urinary albumin excretion in Taiwanese with type 2 diabetes.","date":"2008","source":"American journal of nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/18849600","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16949687","id":"PMC_16949687","title":"Upregulation of human angiotensinogen (AGT) gene transcription by interferon-gamma: involvement of the STAT1-binding motif in the AGT promoter.","date":"2006","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/16949687","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22644634","id":"PMC_22644634","title":"Associations of ACE I/D, AGT M235T gene polymorphisms with pregnancy induced hypertension in Chinese population: a meta-analysis.","date":"2012","source":"Journal of assisted reproduction and genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22644634","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28189547","id":"PMC_28189547","title":"Role of microRNA-29a in the development of diabetic retinopathy by targeting AGT gene in a rat model.","date":"2017","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/28189547","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28455747","id":"PMC_28455747","title":"Oxidative stress promotes myocardial fibrosis by upregulating KCa3.1 channel expression in AGT-REN double transgenic hypertensive mice.","date":"2017","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/28455747","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16352906","id":"PMC_16352906","title":"Haplotype association analysis of AGT variants with hypertension-related traits: the HyperGEN study.","date":"2005","source":"Human heredity","url":"https://pubmed.ncbi.nlm.nih.gov/16352906","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33538177","id":"PMC_33538177","title":"Epigenetics and expression of key genes associated with cardiac fibrosis: NLRP3, MMP2, MMP9, CCN2/CTGF and AGT.","date":"2021","source":"Epigenomics","url":"https://pubmed.ncbi.nlm.nih.gov/33538177","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11095476","id":"PMC_11095476","title":"Influence of the M235T polymorphism of human angiotensinogen (AGT) on plasma AGT and renin concentrations after ethinylestradiol administration.","date":"2000","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/11095476","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24737640","id":"PMC_24737640","title":"Genetic variants of ACE (Insertion/Deletion) and AGT (M268T) genes in patients with diabetes and nephropathy.","date":"2014","source":"Journal of the renin-angiotensin-aldosterone system : JRAAS","url":"https://pubmed.ncbi.nlm.nih.gov/24737640","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22156763","id":"PMC_22156763","title":"Association of polymorphisms in the AGT gene with essential hypertension in the Chinese population.","date":"2011","source":"Journal of the renin-angiotensin-aldosterone system : JRAAS","url":"https://pubmed.ncbi.nlm.nih.gov/22156763","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23790236","id":"PMC_23790236","title":"AGT M235T polymorphisms and ischemic stroke risk: a meta-analysis.","date":"2013","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23790236","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22800767","id":"PMC_22800767","title":"Association of AGT M235T and ACE I/D polymorphisms with the risk of ischemic stroke: meta-analysis in Han Chinese population.","date":"2012","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/22800767","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24092656","id":"PMC_24092656","title":"Occurrence of multiple chloroquine-resistant Pfcrt haplotypes and emergence of the S(agt)VMNT type in Cameroonian Plasmodium falciparum.","date":"2013","source":"The Journal of antimicrobial chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/24092656","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16603315","id":"PMC_16603315","title":"Sequence variants of ACE, AGT, AT1R, and PAI-1 as genetic risk factors for vascular dementia.","date":"2006","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/16603315","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34570572","id":"PMC_34570572","title":"Linkage of blood pressure, obesity and diabetes mellitus with angiotensinogen gene (AGT 704T>C/rs699) polymorphism in hypertensive patients.","date":"2021","source":"Bratislavske lekarske listy","url":"https://pubmed.ncbi.nlm.nih.gov/34570572","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20537141","id":"PMC_20537141","title":"Maternal angiotensinogen (AGT) haplotypes, fetal renin (REN) haplotypes and risk of preeclampsia; estimation of gene-gene interaction from family-triad data.","date":"2010","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20537141","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21666294","id":"PMC_21666294","title":"Mutagenicity associated with O6-methylguanine-DNA damage and mechanism of nucleotide flipping by AGT during repair.","date":"2011","source":"Physical biology","url":"https://pubmed.ncbi.nlm.nih.gov/21666294","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12874613","id":"PMC_12874613","title":"Relation between the angiotensinogen (AGT) M235T gene polymorphism and blood pressure in a large, homogeneous study population.","date":"2003","source":"Journal of human hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/12874613","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19782519","id":"PMC_19782519","title":"Multilocus analysis in candidate genes ACE, AGT, and AGTR1 and predisposition to peripheral arterial disease: role of ACE D/-240T haplotype.","date":"2009","source":"Journal of vascular surgery","url":"https://pubmed.ncbi.nlm.nih.gov/19782519","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17998241","id":"PMC_17998241","title":"The C-532T polymorphism of the angiotensinogen gene is associated with pulse pressure: a possible explanation for heterogeneity in genetic association studies of AGT and hypertension.","date":"2007","source":"International journal of epidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/17998241","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27006715","id":"PMC_27006715","title":"Angiotensinogen (AGT) M235T, AGT T174M and Angiotensin-1-Converting Enzyme (ACE) I/D Gene Polymorphisms in Essential Hypertension: Effects on Ramipril Efficacy.","date":"2015","source":"The open cardiovascular medicine journal","url":"https://pubmed.ncbi.nlm.nih.gov/27006715","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18943011","id":"PMC_18943011","title":"New Anastomosis Groups, AG-T and AG-U, of Binucleate Rhizoctonia spp. Causing Root and Stem Rot of Cut-Flower and Miniature Roses.","date":"2005","source":"Phytopathology","url":"https://pubmed.ncbi.nlm.nih.gov/18943011","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30560688","id":"PMC_30560688","title":"NBGNU: a hypoxia-activated tripartite combi-nitrosourea prodrug overcoming AGT-mediated chemoresistance.","date":"2018","source":"Future medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30560688","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34655849","id":"PMC_34655849","title":"AGT serves as a potential biomarker and drives tumor progression in colorectal carcinoma.","date":"2021","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34655849","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12425365","id":"PMC_12425365","title":"AGT and AT1R gene polymorphism in hypertensive heart disease.","date":"2002","source":"International journal of clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/12425365","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30724623","id":"PMC_30724623","title":"An AGT-based protein-tag system for the labelling and surface immobilization of enzymes on E. coli outer membrane.","date":"2019","source":"Journal of enzyme inhibition and medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30724623","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21248783","id":"PMC_21248783","title":"Epistatic effects of ACE I/D and AGT gene variants on left ventricular mass in hypertensive patients: the HyperGEN study.","date":"2011","source":"Journal of human hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/21248783","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20059472","id":"PMC_20059472","title":"Frequency of the AGT Pro11Leu polymorphism in humans: Does diet matter?","date":"2010","source":"Annals of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20059472","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22977667","id":"PMC_22977667","title":"Effect of GPE-AGT nanoparticle shRNA transfection system mediated RNAi on early atherosclerotic lesion.","date":"2012","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/22977667","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20413984","id":"PMC_20413984","title":"The angiotensinogen AGT p.M235T gene polymorphism may be responsible for the development of severe anaphylactic reactions to insect venom allergens.","date":"2010","source":"International archives of allergy and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20413984","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37399878","id":"PMC_37399878","title":"Hypoxia and CD44 receptors dual-targeted nano-micelles with AGT-inhibitory activity for the targeting delivery of carmustine.","date":"2023","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/37399878","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15483663","id":"PMC_15483663","title":"Context-dependency of the relation between left ventricular mass and AGT gene variants.","date":"2005","source":"Journal of human hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/15483663","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28881807","id":"PMC_28881807","title":"Associations of high altitude polycythemia with polymorphisms in EPHA2 and AGT in Chinese Han and Tibetan populations.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28881807","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28337307","id":"PMC_28337307","title":"Effects of microRNA-29a on retinopathy of prematurity by targeting AGT in a mouse model.","date":"2017","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/28337307","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35030476","id":"PMC_35030476","title":"Associations between AGT, MTHFR, and VEGF gene polymorphisms and preeclampsia in the Chinese population.","date":"2022","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/35030476","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18409009","id":"PMC_18409009","title":"The M235T polymorphism of the AGT gene modifies the risk of coronary artery disease associated with the presence of hypercholesterolemia.","date":"2008","source":"European journal of epidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/18409009","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40203111","id":"PMC_40203111","title":"Preclinical evaluation of AGT mRNA replacement therapy for primary hyperoxaluria type I disease.","date":"2025","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/40203111","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30915766","id":"PMC_30915766","title":"The correlation between AGT gene polymorphism and neonatal hypoxic-ischemic encephalopathy (HIE).","date":"2019","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30915766","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20300047","id":"PMC_20300047","title":"COC use, ACE/AGT gene polymorphisms, and risk of stroke.","date":"2010","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/20300047","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14961043","id":"PMC_14961043","title":"AGT and RH blood group polymorphisms affect blood pressure and lipids in Afro-Caribbeans.","date":"2004","source":"Journal of human hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/14961043","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22791701","id":"PMC_22791701","title":"The interaction of AGT and NOS3 gene polymorphisms with conventional risk factors increases predisposition to hypertension.","date":"2012","source":"Journal of the renin-angiotensin-aldosterone system : JRAAS","url":"https://pubmed.ncbi.nlm.nih.gov/22791701","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8093670","id":"PMC_8093670","title":"Linkage of Agt and Actsk-1 to distal mouse chromosome 8 loci: a new conserved linkage.","date":"1993","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/8093670","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34025779","id":"PMC_34025779","title":"Myocardial Infarction and AGT p.Thr174Met Polymorphism: A Meta-Analysis of 7657 Subjects.","date":"2021","source":"Cardiovascular therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/34025779","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20414195","id":"PMC_20414195","title":"AGT genetic variation, plasma AGT, and blood pressure: An analysis of the Utah Genetic Reference Project pedigrees.","date":"2010","source":"American journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/20414195","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26125750","id":"PMC_26125750","title":"Association between G-217A polymorphism in the AGT gene and essential hypertension: a meta-analysis.","date":"2015","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/26125750","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32356512","id":"PMC_32356512","title":"Association of angiotensin-converting enzyme insertion/deletion (ACE I/D) and angiotensinogen (AGT M235T) polymorphisms with the risk of obesity in a Tunisian population.","date":"2020","source":"Journal of the renin-angiotensin-aldosterone system : JRAAS","url":"https://pubmed.ncbi.nlm.nih.gov/32356512","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25350836","id":"PMC_25350836","title":"Association of AGT M235T gene polymorphism with HSP/HSPN risk.","date":"2014","source":"Renal failure","url":"https://pubmed.ncbi.nlm.nih.gov/25350836","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31858452","id":"PMC_31858452","title":"AGT rs699 and AGTR1 rs5186 gene variants are associated with cardiovascular-related phenotypes in atherosclerotic peripheral arterial obstructive disease.","date":"2019","source":"Irish journal of medical science","url":"https://pubmed.ncbi.nlm.nih.gov/31858452","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26556555","id":"PMC_26556555","title":"Polymorphisms of three genes (ACE, AGT and CYP11B2) in the renin-angiotensin-aldosterone system are not associated with blood pressure salt sensitivity: A systematic meta-analysis.","date":"2015","source":"Blood pressure","url":"https://pubmed.ncbi.nlm.nih.gov/26556555","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23907112","id":"PMC_23907112","title":"Simple renal cysts and hypertension are associated with angiotensinogen (AGT) gene variant in Shiraz population (Iran).","date":"2013","source":"Journal of the renin-angiotensin-aldosterone system : JRAAS","url":"https://pubmed.ncbi.nlm.nih.gov/23907112","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23894329","id":"PMC_23894329","title":"Delivery of therapeutic AGT shRNA by PEG-Bu for hypertension therapy.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23894329","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34678728","id":"PMC_34678728","title":"Development and biological evaluation of AzoBGNU: A novel hypoxia-activated DNA crosslinking prodrug with AGT-inhibitory activity.","date":"2021","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/34678728","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29221188","id":"PMC_29221188","title":"Overexpression of AGT promotes bronchopulmonary dysplasis via the JAK/STAT signal pathway.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29221188","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38053960","id":"PMC_38053960","title":"The Role of AGT, AMPD1, HIF1α, IL-6 Gene Polymorphisms in the Athletes' Power Status: A Meta-Analysis.","date":"2023","source":"Journal of human kinetics","url":"https://pubmed.ncbi.nlm.nih.gov/38053960","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26782563","id":"PMC_26782563","title":"Role of ACE and AGT gene polymorphisms in genetic susceptibility to diabetes mellitus type 2 in a Brazilian sample.","date":"2015","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/26782563","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36986671","id":"PMC_36986671","title":"System Analysis Based on Lipid-Metabolism-Related Genes Identifies AGT as a Novel Therapy Target for Gastric Cancer with Neoadjuvant Chemotherapy.","date":"2023","source":"Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/36986671","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39308860","id":"PMC_39308860","title":"Novel AHR ligand AGT-5 ameliorates type 1 diabetes in mice through regulatory cell activation in the early phase of the disease.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39308860","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10383081","id":"PMC_10383081","title":"Association between AGT T235 variant and microalbuminuria in Canadian Oji-Cree with type 2 diabetes mellitus.","date":"1999","source":"Clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10383081","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31718018","id":"PMC_31718018","title":"Prenatal Diagnosis of Autosomal Recessive Renal Tubular Dysgenesis with Anhydramnios Caused by a Mutation in the AGT Gene.","date":"2019","source":"Diagnostics (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/31718018","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25944852","id":"PMC_25944852","title":"Association of polymorphisms in the AGT gene(M235T, T174M) with ischemic stroke in the Chinese population.","date":"2015","source":"Journal of the renin-angiotensin-aldosterone system : JRAAS","url":"https://pubmed.ncbi.nlm.nih.gov/25944852","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24068433","id":"PMC_24068433","title":"CYP1A1, GCLC, AGT, AGTR1 gene-gene interactions in community-acquired pneumonia pulmonary complications.","date":"2013","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/24068433","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22969920","id":"PMC_22969920","title":"Association between the M235T polymorphism of the AGT gene and cytokines in patients with hypertension.","date":"2011","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22969920","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10969042","id":"PMC_10969042","title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9.","date":"2000","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/10969042","citation_count":2338,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16189514","id":"PMC_16189514","title":"Towards a proteome-scale map of the human protein-protein interaction network.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16189514","citation_count":2090,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1394429","id":"PMC_1394429","title":"Molecular basis of human hypertension: role of angiotensinogen.","date":"1992","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/1394429","citation_count":1612,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12829792","id":"PMC_12829792","title":"Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas.","date":"2003","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12829792","citation_count":1398,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11815627","id":"PMC_11815627","title":"Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11815627","citation_count":1146,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12045255","id":"PMC_12045255","title":"Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin.","date":"2002","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/12045255","citation_count":1101,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29351514","id":"PMC_29351514","title":"The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7).","date":"2018","source":"Physiological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/29351514","citation_count":828,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14718574","id":"PMC_14718574","title":"The human plasma proteome: a nonredundant list developed by combination of four separate sources.","date":"2004","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/14718574","citation_count":658,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8125298","id":"PMC_8125298","title":"Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.","date":"1994","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/8125298","citation_count":492,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15283675","id":"PMC_15283675","title":"Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism.","date":"2004","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/15283675","citation_count":484,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9120024","id":"PMC_9120024","title":"A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro.","date":"1997","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/9120024","citation_count":464,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23488800","id":"PMC_23488800","title":"ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis.","date":"2013","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23488800","citation_count":426,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8513325","id":"PMC_8513325","title":"A molecular variant of angiotensinogen associated with preeclampsia.","date":"1993","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8513325","citation_count":406,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11707427","id":"PMC_11707427","title":"Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11707427","citation_count":379,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16335952","id":"PMC_16335952","title":"Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.","date":"2005","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/16335952","citation_count":350,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23446738","id":"PMC_23446738","title":"Discovery and characterization of alamandine: a novel component of the renin-angiotensin system.","date":"2013","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/23446738","citation_count":305,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14608358","id":"PMC_14608358","title":"WNK4 regulates the balance between renal NaCl reabsorption and K+ secretion.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14608358","citation_count":301,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19059306","id":"PMC_19059306","title":"NADPH oxidases and angiotensin II receptor signaling.","date":"2008","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/19059306","citation_count":300,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15718497","id":"PMC_15718497","title":"Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells.","date":"2005","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/15718497","citation_count":296,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24694986","id":"PMC_24694986","title":"Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate.","date":"2014","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/24694986","citation_count":296,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12663475","id":"PMC_12663475","title":"Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II.","date":"2003","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/12663475","citation_count":295,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10619573","id":"PMC_10619573","title":"The renin-angiotensin-aldosterone system: a specific target for hypertension management.","date":"1999","source":"American journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/10619573","citation_count":288,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15023884","id":"PMC_15023884","title":"Renin-angiotensin system gene polymorphisms and atrial fibrillation.","date":"2004","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/15023884","citation_count":281,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9814470","id":"PMC_9814470","title":"Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II.","date":"1998","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/9814470","citation_count":268,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53128,"output_tokens":4482,"usd":0.113307},"stage2":{"model":"claude-opus-4-6","input_tokens":7966,"output_tokens":3496,"usd":0.190845},"total_usd":0.635453,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":67397,"output_tokens":6150,"usd":0.147221},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":7984,"output_tokens":3312,"usd":0.18408}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2004,\n      \"finding\": \"Human AGT (O6-alkylguanine-DNA alkyltransferase) binds DNA through its helix-turn-helix (HTH) motif in the minor groove (not major groove as previously thought), flips the damaged nucleotide via phosphate rotation involving Tyr114, and transfers the alkyl lesion irreversibly to the active-site Cys145. Crystal structures with O6-methylguanine-containing duplex DNA and a crosslinked inhibitor established these mechanisms.\",\n      \"method\": \"X-ray crystallography of protein-DNA complexes with O6-methylguanine substrate and mechanistic inhibitor N(1),O6-ethanoxanthosine; biochemical validation\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structures with authentic substrate and inhibitor, plus biochemical validation; highly cited foundational paper\",\n      \"pmids\": [\"15221026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Crystal structures of active and alkylated human AGT revealed: (1) an unexpected zinc-stabilized helical bridge joining two domains; (2) an asparagine hinge coupling the active site to the HTH motif; (3) an arginine finger within the HTH motif stabilizes extrahelical O6-alkylguanine without requiring a protein conformational change; (4) cysteine alkylation sterically shifts the HTH recognition helix, coupling repaired-DNA release to opening of the protein fold for biological turnover of the alkylated protein.\",\n      \"method\": \"X-ray crystallography of active, methylated, and benzylated AGT forms; mutational analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple crystal structures plus mutagenesis in a single study; highly cited\",\n      \"pmids\": [\"10747039\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Crystal structure of wild-type human AGT bound to double-stranded DNA with a modified cytosine base shows AGT flips the damaged base into its active-site pocket and also partially flips an undamaged thymine at a second site, suggesting AGT searches for destabilized/distorted base-pairs rather than detecting the adduct itself directly.\",\n      \"method\": \"X-ray crystallography of hAGT-DNA complex\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional interpretation; independent structural study corroborating nucleotide-flipping mechanism\",\n      \"pmids\": [\"15964013\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"AGT employs a two-step nucleotide-flipping mechanism to kinetically discriminate DNA lesions: the protein imposes strain on the DNA duplex and uses a kinetic gate-keeping strategy (rather than thermodynamic discrimination) to identify O6-alkylguanine and thymine adducts before transferring the alkyl group to Cys145.\",\n      \"method\": \"Computational trajectory analysis (rare-event sampling) calibrated against crystal structures and single-molecule experiments\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 method quality (mechanistic pathway elucidation) but single computational study without direct experimental mutagenesis validation\",\n      \"pmids\": [\"18353991\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Human AGT binds single-stranded DNA cooperatively (omega 38–90) with a statistical binding site of ~5 nt and packing densities of ~4 nt/protein, forming overlapping protein arrays along the DNA contour; high binding cooperativity is proposed to enable efficient lesion searching in the context of chromatin.\",\n      \"method\": \"Quantitative equilibrium binding assays (fluorescence anisotropy) with DNAs of 5–78 nt\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — well-characterized in vitro binding with multiple DNA lengths; single lab\",\n      \"pmids\": [\"17138560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Human AGT binds double-stranded DNA cooperatively (omega 23–145) with an apparent binding site of ~4.4 bp and packing density of ~4 bp/protein; overlapping protein-protein contacts along duplex DNA are proposed to facilitate lesion search during DNA replication and chromatin remodeling.\",\n      \"method\": \"Quantitative equilibrium binding assays with duplex DNAs of 11–2686 bp\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic in vitro binding study across a wide length range; single lab, consistent with single-stranded DNA study\",\n      \"pmids\": [\"19061338\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"AGT (MGMT) overexpression in mouse thymus prevents O6-methylguanine-induced lymphomagenesis by removing O6mG adducts before they can cooperate with reduced p53 dosage; demonstrates that unrepaired O6mG lesions are the causative DNA damage driving MNU-induced lymphomas.\",\n      \"method\": \"Transgenic mouse model (human MGMT overexpression in p53+/- background) with MNU treatment; tumor incidence and latency comparison\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic loss-of-function/gain-of-function in vivo with defined phenotypic readout; single lab\",\n      \"pmids\": [\"11536039\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Interferon-gamma upregulates AGT (angiotensinogen) gene transcription in hepatocytes via a STAT1-binding element located between -271 and -279 in the promoter; this represents a pathway separate from IL-6/STAT3 or glucocorticoid receptor mechanisms previously described for AGT regulation.\",\n      \"method\": \"Promoter deletion analysis, EMSA, chromatin immunoprecipitation (ChIP), reporter assays with wild-type and mutant STAT1-binding elements in Hep3B cells\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (EMSA, ChIP, reporter, site-directed mutagenesis) in a single study\",\n      \"pmids\": [\"16949687\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"In primary hyperoxaluria type 1, alanine:glyoxylate aminotransferase (AGT/AGXT) is mistargeted from peroxisomes to mitochondria due to combined effects of a mitochondrial targeting sequence-like sequence and the P11L polymorphism; the peroxisomal import of human AGT is mediated by the PTS1 receptor PEX5p and requires targeting information beyond the canonical PTS1.\",\n      \"method\": \"Biochemical fractionation, protein import assays, mutational analysis of targeting sequences; review of molecular basis established by multiple experimental studies\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — synthesis of multiple experimental studies; subcellular localization with direct functional consequence (metabolic inefficacy in mitochondria)\",\n      \"pmids\": [\"17027096\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"AGT (O6-alkylguanine-DNA alkyltransferase) bound to DNA is markedly more resistant to inactivation by electrophilic species (carbamoylating and alkylating agents) than free AGT, demonstrating that DNA binding protects the active-site cysteine; the carbamoylating component of VNP40101M (IC50 ~13 µM) is ~7-8-fold more potent than the alkylating component (IC50 ~100 µM) against free AGT.\",\n      \"method\": \"In vitro AGT activity assays with cloned human AGT, crosslink formation from O6-chloroethylguanine as readout; pharmacological dissection using selective analogues\",\n      \"journal\": \"Cancer chemotherapy and pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro enzymatic assay with pharmacological dissection; single lab\",\n      \"pmids\": [\"14704831\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"AGT (O6-alkylguanine-DNA alkyltransferase) mediates nucleotide flipping via two successive steps: intercalation of the Arg128 finger residue into the DNA double helix and interaction with the O6MG:C base pair, followed by rotation of the O6MG nucleotide; this mechanism was established by DFT calculations consistent with structural data.\",\n      \"method\": \"High-level density functional theory (DFT) calculations in gas phase and aqueous medium\",\n      \"journal\": \"Physical biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 — computational only, no direct experimental validation in this paper\",\n      \"pmids\": [\"21666294\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"AGT (carbamoylating/alkylating agent sensitivity) — direct inhibition of O6-alkylguanine-DNA alkyltransferase activity by electrophilic species is substrate-accessible: both carbamoylating and alkylating species generated by VNP40101M inactivate cloned human AGT, with DNA protection of AGT demonstrating that DNA-bound AGT requires higher concentrations for inactivation.\",\n      \"method\": \"In vitro AGT repair activity assay; pharmacological analogues to dissect component activities\",\n      \"journal\": \"Cancer chemotherapy and pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct in vitro enzymatic assay with pharmacological controls; mechanistic dissection of inhibitor components\",\n      \"pmids\": [\"14704831\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"mRNA replacement therapy encoding human AGT (alanine:glyoxylate aminotransferase) encapsulated in lipopolyplex produces functional AGT protein targeted to peroxisomes, restoring glyoxylate-to-glycine metabolism; a single 2 mg/kg dose in AgxtQ84-/- rats reduced urinary oxalate by 70%, validating the peroxisomal enzymatic function of AGT in vivo.\",\n      \"method\": \"mRNA transfection, peroxisomal localization confirmation, pharmacokinetics/pharmacodynamics in AgxtQ84-/- rat model, urinary oxalate measurements\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo PK/PD with mechanistic readout (urinary oxalate); single study\",\n      \"pmids\": [\"40203111\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Angiotensinogen (AGT) promotes IL-6-induced inflammatory responses in chondrocytes via the JAK2/STAT3 pathway; miR-149-5p directly binds the AGT 3'UTR to suppress AGT expression, and AGT knockdown blocks the increase of IL-1β, MMP-13, and nitrite in IL-6-stimulated chondrocytes through inhibition of the renin-angiotensin system.\",\n      \"method\": \"Loss-of-function (siRNA knockdown), luciferase reporter assay with mutant binding site, inhibitor treatment, qRT-PCR, western blot in human chondrocyte cells\",\n      \"journal\": \"Clinical and experimental rheumatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — multiple methods including validated miRNA-target interaction with mutagenesis; single lab\",\n      \"pmids\": [\"32141427\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Angiotensinogen (AGT) drives colorectal carcinoma progression (proliferation, migration, invasion, and HUVEC angiogenesis) and induces epithelial-mesenchymal transition via the PI3K/AKT pathway; PI3K/AKT agonist 740Y-P restores EMT impaired by AGT knockdown.\",\n      \"method\": \"AGT knockdown in CRC cell lines, functional assays (proliferation, migration, invasion, tube formation), PI3K/AKT pathway inhibitor/agonist experiments in vitro and in vivo\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — epistasis by pharmacological rescue; multiple cellular readouts; single lab\",\n      \"pmids\": [\"34655849\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Angiotensinogen (AGT) promotes progression of diabetic nephropathy through the TGFβ/Smad2 pathway; AGT knockdown by siRNA reduces TGFβ1 and Smad2 expression and renal fibrosis in db/db mice and in high-glucose-stimulated glomerular mesangial cells.\",\n      \"method\": \"siRNA knockdown of AGT, RNA-seq of kidney tissue, western blot, histopathology in db/db mice and in vitro HG-GMC model\",\n      \"journal\": \"Phytomedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — siRNA knockdown with pathway placement (TGFβ/Smad2) in both in vitro and in vivo models; single lab\",\n      \"pmids\": [\"33571918\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"AGT (angiotensinogen) knockdown via shRNA delivered by GPE nanoparticles to rat liver markedly reduces hepatic AGT mRNA and protein, lowers circulating AGT and Ang II, reduces blood pressure by ~27 mmHg, and attenuates early atherosclerotic lesions in hypertensive atherosclerosis rats.\",\n      \"method\": \"In vivo shRNA knockdown via nanoparticle delivery; PCR, western blot, ELISA, blood pressure measurement, histology in rat model\",\n      \"journal\": \"International journal of clinical and experimental pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo loss-of-function with multiple mechanistic readouts; single lab\",\n      \"pmids\": [\"22977667\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Angiotensinogen (AGT) overexpression in A549 cells activates the JAK/STAT signaling pathway, induces inflammation, and suppresses cell proliferation; these effects are recapitulated by hyperoxia-induced upregulation of AGT, and are modulated by the AGT inhibitor Valsartan and AGT agonist Ang II.\",\n      \"method\": \"AGT overexpression, pharmacological inhibition/stimulation, qPCR, western blot in A549 cells under hyperoxic conditions\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — overexpression with pharmacological modulation; single lab, limited mechanistic depth\",\n      \"pmids\": [\"29221188\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Human AGT (O6-alkylguanine-DNA alkyltransferase/MGMT) searches duplex DNA via cooperative sliding, uses an arginine finger (Arg128) to flip O6-alkylguanine out of the helix through a two-step kinetic mechanism facilitated by Tyr114-mediated phosphate rotation, and irreversibly transfers the alkyl lesion to the active-site Cys145 in a stoichiometric direct-reversal reaction; cysteine alkylation mechanistically couples repaired-DNA release to protein unfolding and biological turnover, while DNA binding protects the active site from inactivation by exogenous electrophiles. The unrelated angiotensinogen protein (also called AGT) is a liver-secreted precursor to angiotensin peptides whose expression is transcriptionally upregulated by IFN-γ/STAT1 and IL-6/STAT3, promotes inflammatory signaling via JAK2/STAT3 and TGFβ/Smad2 pathways in target tissues, and is regulated post-transcriptionally by miR-149-5p; loss of the alanine:glyoxylate aminotransferase isoform (AGXT/AGT) from peroxisomes, where it is imported via PEX5p and the PTS1 signal, causes primary hyperoxaluria type 1 by abolishing glyoxylate-to-glycine conversion.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll systematically classify papers before extracting discoveries.\n\n**Classification:**\n\nThe gene AGT in this corpus refers to two different proteins:\n1. **Angiotensinogen (AGT)** - the precursor to angiotensin II, involved in blood pressure regulation (canonical human AGT)\n2. **O6-alkylguanine-DNA alkyltransferase (AGT/MGMT)** - DNA repair protein (alias collision - this is actually MGMT/MGMT gene)\n3. **Alanine:glyoxylate aminotransferase (AGT/AGXT)** - peroxisomal enzyme (alias collision - this is AGXT gene)\n4. **tRF3-Thr-AGT** - alt-locus product (tsRNA)\n5. **AGT-5** - AHR ligand (unrelated compound)\n6. **E. coli T4 bacteriophage AGT** - alpha-glucosyltransferase (symbol collision - organism-incompatible)\n7. **Rhizoctonia AG-T** - fungal anastomosis group (symbol collision)\n8. **Pfcrt AGT haplotype** - malaria parasite (symbol collision)\n\n**KEEP** (canonical angiotensinogen):\n- PMID:15077204, 17107992 (association/no mechanism), 12404103, 10899077, 16925018 (AGT=MGMT here - EXCLUDE), 9461232, 18575631, 11095476, 10747039 (MGMT-EXCLUDE), 15221026 (MGMT-EXCLUDE), 15964013 (MGMT-EXCLUDE), 17027096 (AGXT-EXCLUDE), 17138560 (MGMT-EXCLUDE), 19061338 (MGMT-EXCLUDE), 34222719, 18353991 (MGMT-EXCLUDE), 14704831 (MGMT-EXCLUDE), 12497201 (MGMT-EXCLUDE), 32141427, 11926202, 33925539, 8895534 (p53 codon-EXCLUDE), 18943011 (Rhizoctonia-EXCLUDE), 24092656 (Plasmodium-EXCLUDE), 16603315, 22977667, 28189547, 28337307, 21666294 (MGMT-EXCLUDE), 16081100 (T4 phage-EXCLUDE), 20029521, 23287839, 27928207, 25031294, 33571918, 21636204, 34643045 (tsRNA-EXCLUDE), 30724623 (MGMT-EXCLUDE), 21248783, 15483663, 28881807, 23907112, 25350836, 22156763, 34655849, 12425365, 26092580, 20414195, 8093670, 16952886, 20300047, 18409009, 20059472 (AGXT-EXCLUDE), 39308860 (AGT-5 AHR ligand-EXCLUDE), 40203111 (AGXT mRNA therapy-EXCLUDE wait - this is alanine:glyoxylate aminotransferase = AGXT gene EXCLUDE), 31858452, 36986671, 26782563, 34570572, 34678728 (MGMT-EXCLUDE), 30560688 (MGMT-EXCLUDE), 37399878 (MGMT-EXCLUDE), 21955333 (MGMT-EXCLUDE), 23894329, 22800767, 23790236, 22644634, 11536039 (MGMT-EXCLUDE), 28455747, 24737640, 22791701, 29221188, 19782519, 17998241, 16352906, 15044674, 20537141, 26556555, 25944852, 10383081, 31718018, 22148914, 20413984, 16949687, 10969042 (ACE2-not AGT), 16189514 (interactome), 1394429, 12477932, 12829792 (Ang1-7/Mas-not AGT), 11815627 (ACE2), 12045255 (renin receptor), 14718574, 21873635, 8125298, 15489334, 23446738, 14608358, 19059306, 15718497, 23488800, 24694986, 12663475, 10619573, 15023884, 9814470, 29351514, 11707427, 16335952, 9120024, 8513325, 15283675, 33961781, 28514442\n\nNow let me carefully identify papers with actual mechanistic findings about canonical **angiotensinogen (AGT)**:\n\n**Definite KEEP with mechanistic content:**\n- PMID:1394429 - linkage + plasma AGT levels differ by genotype → molecular variants as inherited predispositions\n- PMID:9120024 - promoter variant G-6A affects basal transcription (EMSA, reporter assays)\n- PMID:8513325 - T235 variant associated with preeclampsia (association, limited mechanism)\n- PMID:11095476 - T235 allele → greater AGT stimulation after ethinylestradiol (functional RAS study)\n- PMID:9814470 - adipose tissue expresses AGT + RAS enzymes (Northern blot, Western blot, RT-PCR)\n- PMID:16949687 - IFN-γ upregulates AGT via STAT1-binding motif (EMSA, ChIP, reporter assays)\n- PMID:32141427 - AGT promotes IL-6-induced inflammation via JAK2/STAT3; miR-149-5p targets AGT (luciferase, KD)\n- PMID:28189547 - miR-29a targets AGT in diabetic retinopathy (validated targeting)\n- PMID:28337307 - miR-29a targets AGT in ROP (Western blot, knockdown)\n- PMID:33571918 - EPI inhibits AGT→TGFβ/Smad2 pathway in DN (RNA-seq, molecular docking, siRNA)\n- PMID:29221188 - AGT overexpression promotes inflammation via JAK/STAT (cell assay)\n- PMID:34655849 - AGT drives CRC proliferation/migration/invasion (in vitro functional)\n- PMID:12045255 - renin receptor binds renin/prorenin → 4x increase in AGT→AngI conversion efficiency (functional)\n- PMID:10969042 - ACE2 converts AngI to Ang1-9 (AGT product pathway)\n- PMID:36986671 - AGT promotes GC via PI3K/AKT→EMT pathway (functional KD, rescue)\n- PMID:23894329 - AGT shRNA knockdown reduces AGT/AngII, lowers blood pressure (functional in vivo)\n- PMID:22977667 - AGT shRNA reduces AGT mRNA/protein, blood pressure, atherosclerosis (functional)\n- PMID:28455747 - AGT-REN transgenic mice: oxidative stress upregulates KCa3.1 via ERK1/2 (functional)\n- PMID:33925539 - DNA methylation regulates AGT expression (epigenetic mechanism)\n- PMID:8093670 - chromosomal mapping of Agt (mouse Chr 8, human Chr 1) - localization\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"Molecular variants of angiotensinogen (AGT), particularly M235T, are genetically linked to essential hypertension in two independent human cohorts, and plasma angiotensinogen concentrations differ significantly among hypertensive subjects with different AGT genotypes, establishing AGT as a genetic determinant of angiotensinogen levels and blood pressure.\",\n      \"method\": \"Genetic linkage analysis of hypertensive sibships + plasma angiotensinogen quantification stratified by genotype\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — replicated in two geographically separate cohorts with functional plasma level data\",\n      \"pmids\": [\"1394429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The T235 molecular variant of angiotensinogen is significantly associated with preeclampsia in Caucasian and Japanese women, corroborating and extending the link between AGT variants and hypertensive disorders of pregnancy.\",\n      \"method\": \"Genetic association study in two independent ethnically distinct cohorts (Caucasian and Japanese)\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — replicated across two independent populations with consistent direction of effect\",\n      \"pmids\": [\"8513325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"A common nucleotide substitution in the proximal AGT promoter (G-to-A at position −6 upstream of transcription initiation) is associated with essential hypertension and directly reduces basal transcription rate of the AGT gene, as demonstrated by promoter-reporter assays and electrophoretic mobility shift assays showing altered nuclear protein binding at this element.\",\n      \"method\": \"Promoter-reporter (luciferase/CAT) assays + EMSA with nuclear proteins; genetic association in hypertensive subjects\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct functional assay (reporter + EMSA) combined with human genetic association, replicated finding\",\n      \"pmids\": [\"9120024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Human adipose tissue expresses angiotensinogen mRNA and protein, as well as renin, angiotensin-converting enzyme, cathepsin D, and cathepsin G, establishing that angiotensinogen can be processed locally within adipose tissue to produce angiotensin II independently of the circulating renin-angiotensin system.\",\n      \"method\": \"Northern blot (angiotensinogen mRNA), Western blot (angiotensinogen protein in isolated adipocytes), RT-PCR + Southern blot (renin, ACE, cathepsin D, cathepsin G mRNAs) with restriction enzyme verification\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (Northern, Western, RT-PCR) in same study confirming local RAS components\",\n      \"pmids\": [\"9814470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The T235 allele of the AGT gene is associated with greater stimulation of plasma AGT secretion after ethinylestradiol administration in normotensive men, resulting in higher peak plasma AGT concentrations in TT versus MM homozygotes; the renin-angiotensin system readjusts through decreased renin release, blunting the physiological impact of elevated AGT.\",\n      \"method\": \"Controlled pharmacological challenge (ethinylestradiol ± furosemide/captopril) with plasma AGT, renin activity, and active renin measurements in TT vs MM homozygous men\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — controlled in vivo challenge in human subjects with direct hormone measurements, single lab\",\n      \"pmids\": [\"11095476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The renin receptor binds renin and prorenin at the cell surface and, upon renin binding, increases the catalytic efficiency of angiotensinogen conversion to angiotensin I by fourfold, while also activating intracellular MAP kinase signaling (ERK1/ERK2 phosphorylation); the receptor is localized to mesangial glomerular cells and subendothelium co-localizing with renin.\",\n      \"method\": \"Expression cloning; radioligand binding assays; angiotensinogen conversion kinetic assays; phosphorylation/MAP kinase activation assays; confocal microscopy for colocalization\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstituted binding and kinetic assay with multiple orthogonal methods in a single rigorous study\",\n      \"pmids\": [\"12045255\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"IFN-γ upregulates AGT mRNA and promoter activity in hepatocytes through a STAT1-binding element located between −271 and −279 bp in the AGT promoter; EMSA and ChIP assays confirm IFN-γ–induced STAT1 binding to this element, and mutation of the STAT1 site in the full-length promoter reduces IFN-γ responsiveness, defining a pathway distinct from the IL-6/STAT3 or dexamethasone/GR mechanisms.\",\n      \"method\": \"Promoter deletion reporter assays, EMSA, chromatin immunoprecipitation (ChIP), site-directed mutagenesis of STAT1 element in hepatocytes (Hep3B)\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (reporter, EMSA, ChIP, mutagenesis) in single study\",\n      \"pmids\": [\"16949687\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"AGT knockdown in IL-6-stimulated chondrocytes inhibits increases in IL-1β, MMP-13, and nitrite through blocking the renin-angiotensin system; miR-149-5p directly targets the AGT 3′UTR (validated by luciferase reporter and mutant constructs), suppressing AGT expression and thereby attenuating JAK2/STAT3 pathway activation and inflammatory responses in osteoarthritis chondrocytes.\",\n      \"method\": \"Loss-of-function siRNA knockdown; luciferase reporter assay with wild-type and mutant AGT 3′UTR; JAK2/STAT3 pathway inhibitor treatment; RT-qPCR and Western blot in IL-6-stimulated HC-a cells and OA patient cartilage\",\n      \"journal\": \"Clinical and experimental rheumatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — validated miRNA-target interaction with luciferase reporter + functional KD with pathway readout, single lab\",\n      \"pmids\": [\"32141427\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"miR-29a directly targets the AGT 3′UTR and negatively regulates AGT mRNA and protein expression in a rat diabetic retinopathy model; overexpression of miR-29a reduces AGT expression, vascular density, and retinal neovascularization, while knockdown of miR-29a has the opposite effect, establishing an miR-29a→AGT regulatory axis controlling retinal angiogenesis.\",\n      \"method\": \"qRT-PCR, Western blot, ADPase histochemical staining of retinal neovascularization, H&E staining; miR-29a overexpression and knockdown in DR rat model and AR42J cells\",\n      \"journal\": \"Experimental and molecular pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — in vivo functional data with multiple readouts, single lab, no direct luciferase validation of AGT 3′UTR in this paper\",\n      \"pmids\": [\"28189547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"miR-29a suppresses AGT mRNA and protein expression in oxygen-induced retinopathy mouse models; AGT knockdown via si-AGT phenocopies miR-29a overexpression, reducing VEGF, HGF, angiotensin, and angiotensin II protein levels and decreasing retinal neovascularization, placing AGT upstream of angiogenic factor production in ROP pathology.\",\n      \"method\": \"qRT-PCR, Western blot (AGT, VEGF, HGF, ANG, AngII), ADPase histochemical staining, H&E staining; miR-29a mimics/inhibitors and si-AGT in OIR mouse model\",\n      \"journal\": \"American journal of translational research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — functional in vivo with multiple downstream protein readouts; independent confirmation of miR-29a/AGT axis\",\n      \"pmids\": [\"28337307\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In AGT-REN double transgenic hypertensive mice, elevated angiotensin II increases myocardial oxidative stress (elevated MDA, reduced SOD activity), which upregulates KCa3.1 channel protein expression via the ERK1/2 pathway, promoting cardiac fibroblast proliferation and myocardial fibrosis; blockade of ROS (NAC, apocynin) or ERK1/2 (PD98059) reduces KCa3.1 expression and fibrosis.\",\n      \"method\": \"AGT-REN double transgenic mouse model; TRAM-34/losartan/NAC/apocynin/PD98059 pharmacological interventions; Western blot (KCa3.1, p-ERK1/2, β-MHC); biochemical assays (MDA, SOD); histological collagen staining\",\n      \"journal\": \"Pflugers Archiv : European journal of physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo transgenic model with multiple pharmacological interventions and defined pathway readouts, single lab\",\n      \"pmids\": [\"28455747\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"EPI (epiberberine) reduces AGT expression in glomerular mesangial cells and db/db diabetic mice, and AGT siRNA knockdown attenuates proliferation, G2/M arrest, and TGFβ1/Smad2 expression, establishing AGT as an upstream activator of the TGFβ/Smad2 fibrotic pathway in diabetic nephropathy; molecular docking and RNA-seq identified AGT as the key therapeutic target of EPI.\",\n      \"method\": \"RNA-seq of kidney tissue; molecular docking; siRNA knockdown in HG-stimulated glomerular mesangial cells; Western blot (AGT, TGFβ1, Smad2); in vivo db/db mouse treatment with histopathology and renal function assays\",\n      \"journal\": \"Phytomedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA epistasis + in vivo validation with multiple readouts; AGT→TGFβ/Smad2 pathway placement by two orthogonal approaches\",\n      \"pmids\": [\"33571918\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"DNA methylation at CCAAT-enhancer-binding-protein (CEBP) sites in the AGT promoter negatively regulates AGT expression; high salt intake and excess aldosterone cause DNA demethylation at these sites in visceral adipose tissue and heart, converting AGT expression from inactive to active state; low DNA methylation at CEBP-binding sites is associated with increased cardiac AGT expression in salt-sensitive hypertension.\",\n      \"method\": \"Bisulfite sequencing/methylation analysis of AGT promoter; ChIP for CEBP binding; comparison of salt-sensitive hypertensive rats vs controls; human cardiac tissue analysis\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — epigenomic mechanistic data with in vivo correlation, multiple tissues examined\",\n      \"pmids\": [\"33925539\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"AGT promotes colorectal carcinoma cell proliferation, migration, invasion, and HUVEC angiogenesis (induced by CRC-conditioned medium); AGT expression correlates with isoliquiritigenin drug sensitivity, and ISL suppresses CRC progression in vitro.\",\n      \"method\": \"In vitro functional assays (proliferation, migration, invasion, angiogenesis) in CRC cell lines; conditional medium HUVEC angiogenesis assay; drug response analysis (CCLE, CTRP)\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — functional cell assays without defined molecular mechanism or pathway placement for AGT\",\n      \"pmids\": [\"34655849\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Antisense oligonucleotide IONIS-AGT-LRx, administered subcutaneously, significantly reduces plasma angiotensinogen (AGT) protein levels in hypertensive humans in three separate controlled clinical trials, with a favorable safety profile and trends toward blood pressure reduction.\",\n      \"method\": \"Double-blind placebo-controlled Phase 1 and Phase 2 clinical trials; plasma AGT levels measured as pharmacodynamic endpoint\",\n      \"journal\": \"JACC. Basic to translational science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — three independent clinical trials demonstrating on-target AGT reduction in humans with antisense inhibition\",\n      \"pmids\": [\"34222719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"AGT knockdown in gastric cancer cells reduces proliferation and migration, and impairs TGFβ/PI3K/AKT-mediated epithelial-mesenchymal transition (EMT); PI3K/AKT agonist 740Y-P rescues EMT impaired by AGT knockdown and 5-fluorouracil treatment, placing AGT upstream of PI3K/AKT→EMT signaling in gastric cancer and establishing that AGT loss enhances chemotherapy sensitivity in vitro and in vivo.\",\n      \"method\": \"siRNA knockdown of AGT in GC cell lines; Western blot (EMT markers, PI3K/AKT); PI3K/AKT agonist rescue experiment; in vivo xenograft tumor growth assay; bioinformatics risk signature from TCGA/GEO\",\n      \"journal\": \"Pharmaceutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis (rescue experiment) placing AGT in PI3K/AKT/EMT pathway with in vivo validation\",\n      \"pmids\": [\"36986671\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Angiotensinogen (AGT) is a hepatocyte-secreted α2-globulin and the obligate precursor of angiotensin peptides whose expression is transcriptionally upregulated by IFN-γ via a STAT1-binding promoter element and by cytokine/steroid signaling, and is epigenetically regulated by DNA methylation at CEBP sites; AGT is also expressed locally in adipose tissue where the full enzymatic machinery for angiotensin II production is present; the M235T and G-6A promoter variants directly alter plasma AGT levels and basal transcription rate, respectively, predisposing to hypertension and preeclampsia; beyond the classical renin-angiotensin axis, AGT activates downstream JAK2/STAT3 and TGFβ/Smad2 and PI3K/AKT/EMT signaling pathways in inflammatory and oncogenic contexts, and is negatively regulated post-transcriptionally by miR-29a and miR-149-5p.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"The AGT gene symbol maps to three distinct proteins studied in separate literatures: O6-alkylguanine-DNA alkyltransferase (MGMT), angiotensinogen, and alanine:glyoxylate aminotransferase (AGXT). O6-alkylguanine-DNA alkyltransferase is a stoichiometric direct-reversal DNA repair enzyme that binds duplex DNA cooperatively through a helix-turn-helix motif, flips O6-alkylguanine lesions out of the helix via Arg128 intercalation and Tyr114-mediated phosphate rotation, and irreversibly transfers the alkyl group to active-site Cys145; cysteine alkylation shifts the HTH recognition helix, coupling repaired-DNA release to protein unfolding and biological turnover [PMID:15221026, PMID:10747039]. Angiotensinogen is a liver-secreted precursor of vasoactive angiotensin peptides whose transcription is upregulated by IFN-γ/STAT1 and IL-6/STAT3, and which promotes inflammatory and fibrotic signaling in target tissues through JAK2/STAT3, PI3K/AKT, and TGFβ/Smad2 pathways; it is post-transcriptionally suppressed by miR-149-5p [PMID:16949687, PMID:32141427, PMID:33571918]. Alanine:glyoxylate aminotransferase (AGXT) is a peroxisomal enzyme imported via PEX5p that converts glyoxylate to glycine; its mistargeting to mitochondria causes primary hyperoxaluria type 1, and mRNA replacement restores peroxisomal function and reduces urinary oxalate in vivo [PMID:17027096, PMID:40203111].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Determination of how alkyl transfer is structurally coupled to protein turnover: crystal structures of active and alkylated AGT/MGMT revealed that Cys145 alkylation sterically displaces the HTH recognition helix, mechanistically linking DNA release to protein unfolding and degradation.\",\n      \"evidence\": \"X-ray crystallography of active, methylated, and benzylated human AGT forms with mutagenesis\",\n      \"pmids\": [\"10747039\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No structure of the pre-flipping encounter complex on undamaged DNA\",\n        \"Degradation pathway of alkylated AGT not identified\",\n        \"Cooperativity determinants at protein–protein interfaces not mapped\"\n      ]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Establishing that unrepaired O6-methylguanine is the causative lesion in alkylation-induced lymphomagenesis: transgenic MGMT overexpression in mouse thymus prevented MNU-induced lymphomas even in a p53-haploinsufficient background.\",\n      \"evidence\": \"Transgenic mouse model with human MGMT overexpression in p53+/− background; tumor incidence/latency\",\n      \"pmids\": [\"11536039\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Contribution of O6-ethylguanine and larger adducts not tested\",\n        \"Tissue specificity of protection beyond thymus not examined\"\n      ]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Resolving how AGT/MGMT engages DNA and flips the damaged base: co-crystal structures showed HTH motif binding in the minor groove (not major groove), with Tyr114-mediated phosphate rotation enabling nucleotide flipping and alkyl transfer to Cys145.\",\n      \"evidence\": \"X-ray crystallography of AGT–DNA complexes with O6-methylguanine substrate and N1,O6-ethanoxanthosine crosslinked inhibitor\",\n      \"pmids\": [\"15221026\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Kinetic rate constants for flipping and transfer steps not measured\",\n        \"Whether undamaged bases are transiently flipped during lesion search was unclear\"\n      ]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Extending the flipping mechanism to lesion search: a crystal structure showed AGT partially flips an undamaged thymine at a secondary site, suggesting the protein probes DNA stability rather than detecting the adduct directly.\",\n      \"evidence\": \"X-ray crystallography of hAGT–DNA complex with modified cytosine base\",\n      \"pmids\": [\"15964013\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Frequency and energetics of abortive flipping on undamaged DNA not quantified\",\n        \"Role of cooperativity in scanning efficiency not tested\"\n      ]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Quantifying cooperative DNA binding: AGT assembles into overlapping arrays on both single-stranded and double-stranded DNA with high cooperativity (ω up to ~145), packing at ~4 nt/bp per protein, a mode proposed to enable efficient lesion scanning.\",\n      \"evidence\": \"Quantitative fluorescence anisotropy equilibrium binding assays with DNAs of 5–2686 nt/bp\",\n      \"pmids\": [\"17138560\", \"19061338\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Protein–protein contact surfaces mediating cooperativity not structurally defined\",\n        \"Whether cooperative sliding occurs in chromatin context untested\",\n        \"Relationship between cooperativity and repair rate not measured\"\n      ]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identifying IFN-γ/STAT1 as a distinct transcriptional activator of angiotensinogen: promoter analysis and ChIP showed STAT1 binds a specific element (−271 to −279) to upregulate hepatic AGT independently of IL-6/STAT3 or glucocorticoid pathways.\",\n      \"evidence\": \"Promoter deletions, EMSA, ChIP, reporter assays with wild-type and mutant STAT1 sites in Hep3B cells\",\n      \"pmids\": [\"16949687\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"In vivo relevance during systemic inflammation not validated\",\n        \"Interplay between STAT1 and STAT3 elements at endogenous locus not resolved\"\n      ]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Establishing the molecular basis of primary hyperoxaluria type 1: AGT/AGXT mistargeting from peroxisomes to mitochondria (driven by the P11L polymorphism and a cryptic mitochondrial targeting sequence) abolishes glyoxylate-to-glycine conversion; peroxisomal import requires PEX5p and signals beyond the canonical PTS1.\",\n      \"evidence\": \"Biochemical fractionation, protein import assays, mutational analysis of targeting sequences\",\n      \"pmids\": [\"17027096\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Structural basis of PEX5p recognition of AGT beyond PTS1 not determined\",\n        \"Whether residual mitochondrial AGT retains any catalytic activity unclear\"\n      ]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Proposing a two-step kinetic gating mechanism for lesion discrimination: computational trajectory analysis indicated AGT uses Arg128 intercalation followed by nucleotide rotation as successive kinetic checkpoints rather than relying on thermodynamic discrimination.\",\n      \"evidence\": \"Rare-event sampling computational simulations calibrated against crystal structures\",\n      \"pmids\": [\"18353991\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No direct experimental measurement of intermediate states\",\n        \"Predictions not tested by targeted mutagenesis of the kinetic gate\"\n      ]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrating that DNA binding protects AGT active-site cysteine from exogenous electrophiles: DNA-bound AGT required substantially higher concentrations of carbamoylating and alkylating agents for inactivation than free AGT.\",\n      \"evidence\": \"In vitro AGT activity assays with pharmacological dissection of VNP40101M components\",\n      \"pmids\": [\"14704831\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Structural basis of active-site shielding by DNA not determined\",\n        \"Relevance to clinical alkylating-agent resistance not directly tested\"\n      ]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Validating angiotensinogen as a functional driver of hypertension and early atherosclerosis: liver-targeted AGT knockdown via shRNA nanoparticles reduced circulating AGT and Ang II, lowered blood pressure ~27 mmHg, and attenuated atherosclerotic lesions in rats.\",\n      \"evidence\": \"In vivo shRNA knockdown via GPE nanoparticles; blood pressure, ELISA, histology in rat model\",\n      \"pmids\": [\"22977667\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Long-term durability and off-target effects of nanoparticle delivery not assessed\",\n        \"Relative contribution of Ang II vs. other angiotensin peptides not dissected\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Mapping angiotensinogen's downstream signaling in disease contexts: AGT promotes inflammatory and fibrotic responses through JAK2/STAT3 (chondrocytes), TGFβ/Smad2 (diabetic nephropathy), and PI3K/AKT (colorectal carcinoma EMT); miR-149-5p suppresses AGT by directly targeting the 3′UTR.\",\n      \"evidence\": \"siRNA/shRNA knockdown, luciferase reporter assays with mutant miR-149-5p binding sites, pathway inhibitor/agonist epistasis experiments in multiple cell types and in vivo models\",\n      \"pmids\": [\"32141427\", \"33571918\", \"34655849\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether AGT signals through processed angiotensin peptides or the intact protein in these contexts is often unresolved\",\n        \"Specificity of miR-149-5p regulation in vivo not confirmed\",\n        \"No unified model integrating tissue-specific pathway selection\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Providing therapeutic proof-of-concept for AGT/AGXT mRNA replacement: lipopolyplex-delivered mRNA encoding human AGXT restored peroxisomal localization and glyoxylate-to-glycine conversion, reducing urinary oxalate by 70% in an Agxt-knockout rat model.\",\n      \"evidence\": \"mRNA transfection with peroxisomal localization confirmation, PK/PD in AgxtQ84−/− rats\",\n      \"pmids\": [\"40203111\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Durability beyond single dose not established\",\n        \"Whether mRNA therapy corrects mistargeted (P11L) AGT rather than null alleles not tested\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the structural basis of cooperative protein–protein contacts enabling AGT/MGMT sliding on chromatin DNA; the identity of the ubiquitin ligase pathway that degrades alkylated MGMT; whether angiotensinogen exerts receptor-independent signaling distinct from processed angiotensin peptides; and the molecular determinants enabling PEX5p to recognize AGXT beyond the minimal PTS1 signal.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No structural model of the cooperative AGT–AGT interface on DNA\",\n        \"Degradation machinery for alkylated MGMT not identified\",\n        \"Receptor-independent signaling of intact angiotensinogen not tested\",\n        \"Full PEX5p recognition determinants for AGXT not mapped\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 2, 3]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 2, 4, 5]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [16]},\n      {\"term_id\": \"GO:0016853\", \"supporting_discovery_ids\": [8, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 2, 4, 5]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [16, 13]},\n      {\"term_id\": \"GO:0005777\", \"supporting_discovery_ids\": [8, 12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [0, 1, 2, 3, 6]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 13, 14, 15]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [8, 12]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"PEX5\",\n      \"STAT1\",\n      \"STAT3\",\n      \"JAK2\",\n      \"SMAD2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"Angiotensinogen (AGT) is the obligate secreted precursor of the angiotensin peptide family and a central determinant of renin–angiotensin system (RAS) activity, blood pressure homeostasis, and tissue-level angiotensin II signaling. The M235T coding variant and G-6A promoter variant directly modulate plasma AGT levels and basal transcription rate, respectively, conferring genetic susceptibility to essential hypertension and preeclampsia [PMID:1394429, PMID:8513325, PMID:9120024]. AGT transcription in hepatocytes is upregulated by IFN-γ through a STAT1-binding promoter element and is epigenetically tuned by DNA methylation at CEBP sites, while post-transcriptionally miR-29a and miR-149-5p target the AGT 3′UTR to suppress expression [PMID:16949687, PMID:33925539, PMID:32141427, PMID:28189547]. Beyond classical renin-mediated cleavage—enhanced by the renin receptor at cell surfaces [PMID:12045255]—AGT is expressed in adipose tissue with a complete local RAS machinery and signals through downstream TGFβ/Smad2, PI3K/AKT/EMT, and JAK2/STAT3 pathways in inflammatory, fibrotic, and oncogenic contexts [PMID:9814470, PMID:33571918, PMID:36986671, PMID:32141427].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Establishing AGT as a genetic determinant of blood pressure answered whether angiotensinogen itself—not just downstream RAS components—could be rate-limiting for hypertension risk.\",\n      \"evidence\": \"Genetic linkage analysis of hypertensive sibships in two independent cohorts with plasma AGT quantification stratified by M235T genotype\",\n      \"pmids\": [\"1394429\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether M235T is causal or in linkage disequilibrium with the true functional variant\",\n        \"Mechanism by which M235T alters AGT secretion or stability unresolved\"\n      ]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Extension of the AGT T235 association to preeclampsia demonstrated that this variant predisposes to hypertensive disorders beyond essential hypertension, broadening the clinical significance of AGT variation.\",\n      \"evidence\": \"Genetic association study in independent Caucasian and Japanese cohorts of preeclamptic women\",\n      \"pmids\": [\"8513325\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Molecular mechanism linking elevated AGT to placental pathology not defined\",\n        \"Whether preeclampsia risk is mediated by maternal or fetal AGT genotype unclear\"\n      ]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Identification of the G-6A promoter variant as a functional cis-regulatory element resolved how a non-coding AGT variant directly alters transcription rate and nuclear protein binding, mechanistically linking promoter variation to plasma AGT levels.\",\n      \"evidence\": \"Promoter-reporter assays (luciferase/CAT) and EMSA with nuclear extracts in human cells, plus genetic association\",\n      \"pmids\": [\"9120024\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Identity of the nuclear factor whose binding is altered at −6 not determined\",\n        \"Contribution of G-6A versus M235T in cis not fully disentangled\"\n      ]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstrating local AGT expression together with renin, ACE, and cathepsins in adipose tissue established that angiotensin II can be generated in a tissue-autonomous manner, independent of hepatic secretion.\",\n      \"evidence\": \"Northern blot, Western blot, RT-PCR with restriction verification in human adipocytes\",\n      \"pmids\": [\"9814470\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Quantitative contribution of adipose-derived versus hepatic AGT to circulating angiotensin peptides unknown\",\n        \"Regulatory signals controlling adipose AGT expression not characterized\"\n      ]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Discovery that the renin receptor enhances AGT-to-angiotensin I conversion fourfold upon renin binding provided a cell-surface mechanism amplifying local RAS activity and added a non-proteolytic signaling dimension (ERK1/2) to renin–AGT interaction.\",\n      \"evidence\": \"Expression cloning, radioligand binding, kinetic conversion assays, and ERK phosphorylation assays with confocal colocalization in mesangial cells\",\n      \"pmids\": [\"12045255\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether the renin receptor alters AGT conformation or merely concentrates renin at the surface not resolved\",\n        \"In vivo contribution of receptor-bound versus soluble renin to AGT cleavage not quantified\"\n      ]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Mapping a STAT1-binding element in the AGT promoter responsive to IFN-γ defined a cytokine-driven transcriptional pathway for AGT distinct from the known IL-6/STAT3 and glucocorticoid mechanisms, linking innate immune activation to RAS induction.\",\n      \"evidence\": \"Promoter deletion reporters, EMSA, ChIP, and site-directed mutagenesis in Hep3B hepatocytes\",\n      \"pmids\": [\"16949687\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether STAT1-driven AGT induction occurs in non-hepatic tissues not tested\",\n        \"Physiological contexts in which IFN-γ-mediated AGT upregulation is rate-limiting for angiotensin II generation unknown\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identification of miR-29a and miR-149-5p as direct post-transcriptional repressors of AGT via its 3′UTR established a new regulatory layer, with functional consequences for retinal neovascularization (miR-29a) and chondrocyte inflammation through JAK2/STAT3 (miR-149-5p).\",\n      \"evidence\": \"Luciferase 3′UTR reporter with wild-type and mutant constructs (miR-149-5p); miR-29a overexpression/knockdown in diabetic retinopathy and OIR rodent models with AGT protein and angiogenic readouts; siRNA epistasis in chondrocytes\",\n      \"pmids\": [\"32141427\", \"28189547\", \"28337307\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"miR-29a targeting of AGT 3′UTR lacks direct luciferase validation in the cited study\",\n        \"Whether these miRNAs regulate hepatic AGT output in vivo not examined\",\n        \"Relative contribution of AGT suppression versus other targets of miR-29a to the anti-angiogenic phenotype unresolved\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"AGT-REN double transgenic mice demonstrated that sustained AGT/angiotensin II elevation drives myocardial fibrosis via ROS-mediated ERK1/2 activation of KCa3.1 channels, placing AGT upstream of oxidative-stress-dependent ion channel remodeling in cardiac fibroblasts.\",\n      \"evidence\": \"Double transgenic mouse model with pharmacological interventions (losartan, NAC, apocynin, PD98059, TRAM-34); Western blot and biochemical assays for pathway components\",\n      \"pmids\": [\"28455747\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether KCa3.1 upregulation is a direct consequence of angiotensin II receptor signaling or secondary to ROS accumulation not fully dissected\",\n        \"Single lab; independent replication pending\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Epigenetic regulation of AGT was defined by showing that DNA methylation at CEBP sites in the AGT promoter acts as an on/off switch: demethylation by high salt and aldosterone activates AGT transcription in adipose and cardiac tissue, linking dietary and hormonal inputs to epigenomic control of local RAS.\",\n      \"evidence\": \"Bisulfite sequencing and ChIP for CEBP binding in salt-sensitive hypertensive rats and human cardiac tissue\",\n      \"pmids\": [\"33925539\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Causal relationship between demethylation and CEBP binding not established by interventional demethylation\",\n        \"Whether methylation changes are reversible upon salt restriction not tested\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Placing AGT upstream of TGFβ/Smad2 signaling in diabetic nephropathy and demonstrating that AGT knockdown attenuates fibrotic responses in mesangial cells broadened AGT's effector role beyond hemodynamics to organ fibrosis.\",\n      \"evidence\": \"siRNA knockdown in high-glucose-stimulated mesangial cells with Western blot for TGFβ1/Smad2; in vivo validation in db/db mice treated with epiberberine\",\n      \"pmids\": [\"33571918\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether fibrotic effect is mediated by angiotensin II or by intact AGT protein not distinguished\",\n        \"Specificity of epiberberine for AGT versus off-target effects not fully controlled\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Antisense oligonucleotide-mediated AGT suppression in hypertensive humans validated AGT as a druggable therapeutic target, providing clinical proof-of-concept that reducing the precursor pool itself can modulate RAS activity.\",\n      \"evidence\": \"Phase 1 and Phase 2 double-blind placebo-controlled trials of IONIS-AGT-LRx with plasma AGT as pharmacodynamic endpoint\",\n      \"pmids\": [\"34222719\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Long-term safety and blood-pressure efficacy not yet established in Phase 3 trials\",\n        \"Effect on tissue (non-hepatic) AGT pools not assessed\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstration that AGT knockdown impairs PI3K/AKT-mediated EMT in gastric cancer—rescued by a PI3K agonist—positioned AGT as an upstream activator of an oncogenic signaling axis and suggested AGT loss sensitizes tumors to 5-fluorouracil.\",\n      \"evidence\": \"siRNA knockdown with PI3K/AKT agonist rescue in GC cell lines; Western blot for EMT markers; xenograft tumor growth assay\",\n      \"pmids\": [\"36986671\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether the oncogenic effect requires angiotensin II generation or is a direct property of AGT protein not resolved\",\n        \"Relevance to human gastric cancer in vivo beyond xenograft models not established\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved whether AGT exerts signaling functions independent of its cleavage to angiotensin peptides, and structural determinants of variant-specific differences in renin cleavage efficiency or secretion rate have not been defined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No crystal structure of full-length human AGT in complex with renin to explain M235T kinetic differences\",\n        \"Angiotensin-independent functions of intact AGT protein not tested by cleavage-resistant mutants\",\n        \"Relative contribution of hepatic versus tissue-specific AGT to local and systemic angiotensin generation in humans not quantified\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [5, 10, 11, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 3, 4, 14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 7, 10, 11, 15]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [0, 2, 14]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 13, 15]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"REN\",\n      \"ATP6AP2\",\n      \"ACE\",\n      \"TGFB1\",\n      \"SMAD2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}